Dose-Dense Chemotherapy As Adjuvant Treatment for Breast Cancer

Atkins, Carl D.

doi:10.1200/jco.2004.99.114

Cited by 4 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, baseline PTEN or HIF1-α levels were shown not to be associated with single agent Temsirolimus response (Figlin et al, 2009; Table 3). Furthermore, in a retrospective subgroup analysis from a phase II clinical trial of ARCC (Atkins et al, 2004) including 20 patients (Cho et al, 2007), carbonic anhydrase IX (CA9), p-AKT, and PTEN protein expression levels using IHC or VHL mutation status were shown not to be significantly associated with single agent Temsirolimus response. There was, however, a significant positive association between higher p-rpS6 expression, a downstream effector of mTORC1 (Figure 1), and clinical Temsirolimus response (Cho et al, 2007).…”

Section: Genomic Determinants Of Pi3k Pathway Inhibitor Response In Cmentioning

confidence: 99%

Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer

Weigelt¹,

Downward²

2012

Front. Oncol.

View full text Add to dashboard Cite

The phosphoinositide 3-kinase (PI3K) pathway is frequently activated in cancer as a result of genetic (e.g., amplifications, mutations, deletions) and epigenetic (e.g., methylation, regulation by non-coding RNAs) aberrations targeting its key components. Several lines of evidence demonstrate that tumors from different anatomical sites depend on the continued activation of this pathway for the maintenance of their malignant phenotype. The PI3K pathway therefore is an attractive candidate for therapeutic intervention, and inhibitors targeting different components of this pathway are in various stages of clinical development. Burgeoning data suggest that the genomic features of a given tumor determine its response to targeted small molecule inhibitors. Importantly, alterations of different components of the PI3K pathway may result in distinct types of dependencies and response to specific therapeutic agents. In this review, we will focus on the genomic determinants of response to PI3K, dual PI3K/mechanistic target of rapamycin (mTOR), mTOR, and AKT inhibitors in cancer identified in preclinical models and clinical trials to date, and the development of molecular tools for the stratification of cancer patients.

show abstract